CRDF Cardiff Oncology1.85+0.01 (+0.5%)
CRDF Cardiff Oncology1.62-0.05 (-3.0%)
CRDF Cardiff Oncology1.66-0.07 (-4.1%)
CRDF Cardiff Oncology1.84-0.07 (-3.7%)
CRDF Cardiff Oncology1.95-0.99 (-33.7%)
Premarket Decliner
CRDF Cardiff Oncology2.94+0.04+1.4%
Premarket:2.24-0.70 (-23.8%)
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
Globe NewswireTue, 27-Jan 7:05 AM